Antiatherosclerotic effects of oral naftidrofuryl in cholesterol-fed rabbits involve inhibition of neutrophil function

J Cardiovasc Pharmacol. 1995 May;25(5):774-81. doi: 10.1097/00005344-199505000-00013.

Abstract

We investigated the action of oral naftidrofuryl, a serotonin (5-HT2)antagonist, on atheromatous plaque formation, endothelial function, and neutrophil activity in cholesterol-fed (1% for 12 weeks) rabbits. Cholesterol feeding caused almost complete (84 +/- 4%) coverage of the aortic surface with atheromas and a marked intimal thickening. The endothelium-dependent relaxation to acetylcholine (ACh 1 nM-10 microM) and substance P (30 nM) was considerably reduced, whereas the relaxing effect to the endothelium-independent nitric oxide donor linsidomine (SIN-1) (100 microM) was unchanged. Treatment of hypercholesterolemic rabbits with naftidrofuryl (50 mg/kg body weight) resulted in a marked (54 +/- 6%, p < 0.05) reduction in aortic plaque formation. Endothelium-dependent relaxation to ACh was significantly improved in rings of both thoracic aorta: 33 +/- 5 versus 14 +/- 5% (p < 0.05) and abdominal aorta 68 +/- 9 versus 37 +/- 10% (p < 0.05). Similar results were obtained with substance P, but the responses to SIN-1 were unchanged. Zymosan-induced, luminol-enhanced chemiluminescence of polymorphonuclear leukocytes (PMN) was markedly stimulated in cholesterol-fed rabbits. Naftidrofuryl reduced this hyperreactivity to that of control rabbits. There was no change by naftidrofuryl in any of these parameters in control rabbits, precluding a direct action of the compound in nonhypercholesterolemic conditions. These data demonstrate significant endothelium-protective actions of long-term oral naftidrofuryl in cholesterol-fed rabbits that involve inhibition of cholesterol-induced neutrophil activation.

MeSH terms

  • Acetylcholine / pharmacology
  • Administration, Oral
  • Animals
  • Aorta, Abdominal / drug effects
  • Aorta, Abdominal / pathology
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / pathology
  • Arteriosclerosis / drug therapy*
  • Cholesterol / blood
  • Cholesterol, Dietary / administration & dosage
  • Disease Models, Animal
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / pathology
  • Fibrinogen / metabolism
  • Luminescent Measurements
  • Luminol / pharmacology
  • Male
  • Molsidomine / analogs & derivatives
  • Molsidomine / pharmacology
  • Muscle Contraction / drug effects
  • Muscle Relaxation / drug effects
  • Muscle, Smooth, Vascular / drug effects*
  • Nafronyl / administration & dosage
  • Nafronyl / pharmacology
  • Nafronyl / therapeutic use*
  • Neutrophils / drug effects*
  • Neutrophils / physiology
  • Nitric Oxide / metabolism
  • Rabbits
  • Random Allocation
  • Substance P / pharmacology
  • Vasodilator Agents / pharmacology
  • Zymosan / pharmacology

Substances

  • Cholesterol, Dietary
  • Vasodilator Agents
  • Nitric Oxide
  • Substance P
  • Nafronyl
  • Luminol
  • linsidomine
  • Fibrinogen
  • Zymosan
  • Cholesterol
  • Molsidomine
  • Acetylcholine